Medical Specialty >> Pharmacy
Over 40% of Antibiotics Could Be ‘Inappropriately’ Prescribed
7:00 PM CST.
By Steven ReinbergHealthDay Reporter Read article
- CBD Medicine May Help Ease Another Form of Seizure
- FDA Approves First Generic Forms of MS Drug Gilenya
- FDA Testing Levels of Carcinogen in Diabetes Drug Metformin
- BPA Levels in Humans Are Underestimated: Study
JOURNAL UPDATE
Factors Predict Adverse Opioid-Related Outcomes in Cancer Survivors
7:00 PM CST. Demographic, cancer, and treatment factors can predict outcomes with high level of discrimination- Evidence Supports Use of High-Dose Aspirin for Migraine
- Antibiotic Exposure May Be Tied to Risk for Parkinson Disease
- Cost Saving-Related Rx Nonadherence Found for 7 Percent With HIV
MONTHLY JOURNAL SUMMARY
November 2019 Briefing - Pharmacy
December 02, 2019. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
Ted Lain, MD.
Clinical trial investigator Dr. Ted Lain comments on the results of the OPAL study, a Phase 2b clinical trial which evaluated the efficacy of a novel topical gel formulation of the antibiotic minocycline (BPX-01) in reducing the number of inflammatory lesions in patients with moderate-to-severe inflammatory,…
Bevacizumab for breast cancer: FDA grants a stay of execution
Dr. Alberto De la Guerra.
The Food and Drug Administration has after repeated delays proposed removing metastatic breast cancer as an indication from the Avastin label. The proposal is being contested by Roche/Genentech, the drug’s maker. In this article we review the evidence for and against this decision.
MEDICAL FOCUS
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By namabcAs I understand, this is a great step of development that we can use to save many people from horrible diseases. and i also hope Dr.Lain and your partners…
